Amgen (AMGN) News Today

Amgen Inc. (NASDAQ: AMGN) shares have decreased sharply as investors reassess the prospects for the company’s experimental cholesterol treatment olpasiran, despite positive oncology trial news.

• Positive Sentiment: Amgen reported that IMDELLTRA, combined with AstraZeneca’s Imfinzi, significantly improved overall survival in a Phase 3 trial for first-line extensive-stage small-cell lung cancer. The study also met progression-free survival and response-rate endpoints, strengthening the commercial outlook for the oncology franchise. Amgen IMDELLTRA Phase 3 results
• Positive Sentiment: William Blair maintained a Buy rating, citing the Phase 3 success of IMDELLTRA, while UBS said olpasiran could still demonstrate meaningful cardiovascular risk reduction. These views provide some support against the broader selloff. William Blair maintains Buy rating
• Neutral Sentiment: Broader market pressure from surging oil prices, Middle East tensions and U.S.-Canada trade friction is adding to volatility, although the primary catalyst for Amgen appears company- and sector-specific. Market declines amid oil and geopolitical concerns
• Negative Sentiment: Novartis’ Phase 3 pelacarsen trial failed to reduce cardiovascular events, even though it lowered Lp(a). Investors are treating the result as evidence that lowering the biomarker may not translate into fewer heart attacks or strokes, raising the bar for Amgen’s olpasiran program and clouding the outlook for the entire Lp(a) drug class. Novartis cholesterol drug setback
• Negative Sentiment: BMO downgraded Amgen to Market Perform from Outperform, citing limited near-term upside and a more balanced risk-reward profile. The downgrade amplified selling pressure following the Novartis read-through concerns. BMO downgrades Amgen